We consult to a wide range of clients from multinational pharmaceutical corporations to SMEs and university spin-outs – across a variety of healthcare market sectors:

  • Pharmaceuticals: Primary and Speciality Care
  • Rare Diseases/Orphan Drugs
  • Cell-therapies and Regenerative Medicine
  • Medical Devices: Consumables/Disposables and Equipment
  • Diagnostics: Point-of-Care, Imaging and Laboratory services

Our therapeutic category experience includes:

  • Allergy
  • Analgesia/Pain management
  • Advanced Therapy Medicinal Products (ATMPs)
  • Cardiovascular/Circulatory
  • Dermatology
  • Diabetes
  • Ophthalmology
  • Gastro-intestinal
  • Infectious disease / Microbiology
  • Intensive Care
  • Neurology / Multiple Sclerosis
  • Oncology
  • Haematology
  • Respiratory
  • Rheumatology
  • Smoking Cessation
  • Women's Health
  • Wound Care
Character presenting stats

Strategic Brand Development

The collection and analysis of market and patient data, gathering insights and evaluating alternative scenarios. To optimise the positioning of a technology with specific attributes, benefits and values to create a distinctive, sustainable, brand.

Example Projects

  • Early-stage modelling for assessment of new dermatological technologies in France, UK and USA
  • Strategic assessment and business plan review of in-licensing opportunity for mid-cap pharma client
  • Developing a company-wide launch-readiness programme for treatment of neutropenia
  • Strategic positioning of treatment for Cytomegalovirus (CMV) in early pregnancy
  • Scientific Advice Briefing Books for CAR T-cell products in Oncology
Synthesis funnel

Evidence Synthesis

The use of techniques to identify the best evidence to address a policy or business-relevant question through the comprehensive assimilation of relevant information.

Example Projects

  • Systematic review of clinical effectiveness studies in numerous therapeutic categories (including Ophthalmology, Oncology, Cardiovascular, Dermatology)
  • Review of economic evaluations of dermatological interventions for HTA
  • Literature review to characterise the burden of disease in diffuse large B-cell lymphoma
  • Systematic review and analysis to support the case for a surrogate endpoint
  • Needs analysis for treatment in non-small-cell lung cancer (NSCLC)
Markov chain

Health Economics

The analysis of issues related to efficiency, effectiveness and value as applied to the topic of healthcare - economic concerns how society allocates its resources among alternative uses.

Example Projects

  • Strategic health economics and outcomes research (HEOR) consulting in oncology including CAR T-cell therapy
  • Pan-European cost-utility model in chronic obstructive pulmonary disease (COPD)
  • Cost-benefit analysis of programme to assess risk of cardiovascular disease/stroke
  • Economic evaluation in diagnosis and management of osteoarthritis
  • Development of easy to use, compelling, budget impact models (BIMs) for various therapies
  • Economic analysis of data and model in pain management
  • Analysis of NHSE submission in transplantation
CBalancing Value Scales

Pricing and Reimbursement

The process of establishing a price and obtaining a positive reimbursement decision and/or formulary listing status for a pharmaceutical or med-tech product.

Example Projects

  • Pan-European market access pricing and reimbursement study for treatment in acute lymphocytic leukaemia
  • Payer assessment/pricing analysis of treatment for prostate cancer
  • Drug Tariff application for NHS reimbursement of a wound care product
  • Pricing submission for Vitamin A for use in cystic fibrosis
HTA character and people

Health technology assessment (HTA)

The systematic evaluation of properties, effects, and/or impacts of health technology: a multidisciplinary process to evaluate a healthcare intervention or healthcare technology.

Example Projects

  • NICE approval of the first stem cell technology in UK through Single Technology Appraisal route. Included SLR and additional analysis of data to demonstrate long-term benefit
  • Successful health technology assessment (HTA) submissions e.g. psoriasis (NICE, SMC) and advanced gastric cancer (SMC)
  • Production of early scientific advice briefing books / dossiers in oncology for HTA in 3 EU countries
CVD Synthesis diagram

Value Communications

The development of clear value propositions, underpinned by the evidence, to help communicate the unique benefits of a product or intervention.

Example Projects

  • Publications based on cost-effectiveness analysis to demonstrate value of wound care product in NHS
  • Review to support evidence framework in prostate cancer
  • Development of publication on the applicability of HTA methodology in the evaluation of stem-cell therapies
  • Creation of impactful pharma market core/global value dossiers